| Ab | antibody |
| ACIP | Advisory Committee on Immunization Practices |
| AReSVi-006 | phase 3 trial of RSVPreF3 in older adults |
| AS01 | adjuvant system 01 (GlaxoSmithKline) |
| AS03 | adjuvant system 03 (GlaxoSmithKline) |
| BA.1 | SARS-CoV-2 Omicron sublineage BA.1 |
| BA.2 | SARS-CoV-2 Omicron sublineage BA.2 |
| BA.2.86 | SARS-CoV-2 Omicron sublineage BA.2.86 |
| BA.4 | SARS-CoV-2 Omicron sublineage BA.4 |
| BA.5 | SARS-CoV-2 Omicron sublineage BA.5 |
| BCR | B-cell receptor |
| bnAb(s) | broadly neutralizing antibody(ies) |
| BNT162b2 | Pfizer-BioNTech COVID-19 mRNA vaccine |
| CDC | US Centers for Disease Control and Prevention |
| ChAdOx1 | chimpanzee adenovirus Oxford 1 (viral vector) |
| CIDRAP | Center for Infectious Disease Research and Policy |
| COBRA | computationally optimized broadly reactive antigen |
| Com-COV | Comparing COVID-19 Vaccine Schedule Combinations trial |
| Com-COV2 | Comparing COVID-19 Vaccine Schedule Combinations trial 2 |
| COVID-19 | coronavirus disease 2019 |
| cryo-EM | cryogenic electron microscopy |
| F | fusion protein (RSV surface glycoprotein) |
| FDA | US Food and Drug Administration |
| FDC | follicular dendritic cell |
| FI-RSV | formalin-inactivated respiratory syncytial virus vaccine |
| G | attachment glycoprotein (RSV surface protein) |
| GC(s) | germinal center(s) |
| H1 | hemagglutinin subtype 1 |
| H1N1 | influenza A hemagglutinin 1, neuraminidase 1 |
| H2 | hemagglutinin subtype 2 |
| H2N2 | influenza A hemagglutinin 2, neuraminidase 2 |
| H3 | hemagglutinin subtype 3 |
| H3N2 | influenza A hemagglutinin 3, neuraminidase 2 |
| H5 | hemagglutinin subtype 5 |
| H5N1 | influenza A hemagglutinin 5, neuraminidase 1 |
| H7 | hemagglutinin subtype 7 |
| H7N9 | influenza A hemagglutinin 7, neuraminidase 9 |
| HA | hemagglutinin |
| HAI | hemagglutination inhibition |
| HARMONIE | nirsevimab post-authorization real-world effectiveness study |
| IBV | influenza B virus |
| IgG | immunoglobulin G |
| IgM | immunoglobulin M |
| JN.1 | SARS-CoV-2 Omicron sublineage JN.1 |
| KP.2 | SARS-CoV-2 Omicron sublineage KP.2 |
| KP.3 | SARS-CoV-2 Omicron sublineage KP.3 |
| LAIV | live attenuated influenza vaccine |
| mAb(s) | monoclonal antibody(ies) |
| MATISSE | phase 3 trial of RSVpreF maternal vaccine |
| MELODY | phase 3 trial of nirsevimab in healthy term and late-preterm infants |
| MERS-CoV | Middle East respiratory syndrome coronavirus |
| MF59 | squalene-based oil-in-water adjuvant |
| MMWR | Morbidity and Mortality Weekly Report (US CDC) |
| mRNA | messenger RNA |
| NA | neuraminidase |
| NK | natural killer (cell) |
| OAS | original antigenic sin |
| post-F | postfusion conformation of RSV F protein |
| pre-F | prefusion conformation of RSV F protein |
| RBD | receptor-binding domain (of SARS-CoV-2 spike) |
| RSV | respiratory syncytial virus |
| RSV-A | respiratory syncytial virus subgroup A |
| RSV-B | respiratory syncytial virus subgroup B |
| RSVpreF | bivalent RSV prefusion F vaccine (Pfizer, Abrysvo) |
| RSVPreF3 | RSV prefusion F vaccine (GlaxoSmithKline, Arexvy) |
| S | spike protein (of SARS-CoV-2) |
| S1 | spike subunit 1 |
| S2 | spike subunit 2 |
| S2P6 | human monoclonal antibody targeting the conserved S2 stem |
| SARS | severe acute respiratory syndrome |
| SARS-CoV | severe acute respiratory syndrome coronavirus |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus 2 |
| SHM | somatic hypermutation |
| Tfh | T follicular helper (cell) |
| Th1 | T helper type 1 |
| Th2 | T helper type 2 |
| UK | United Kingdom |
| US | United States |
| VE | vaccine effectiveness |
| VLP | virus-like particle |
| WHO | World Health Organization |
| WT | wild type |
| Wuhan-Hu-1 | ancestral SARS-CoV-2 reference sequence |
| XBB | SARS-CoV-2 recombinant Omicron lineage XBB |
| XBB.1.5 | SARS-CoV-2 Omicron sublineage XBB.1.5 |
| XEC | SARS-CoV-2 Omicron recombinant sublineage XEC |
| ZOE-50 | phase 3 trial of the adjuvanted zoster subunit vaccine |